Dana-farber-cancer Institute Inc.

Xiamen University

The Scripps Research Institute

University of Pittsburgh

The United States Government As Represented by the Department of Veterans Affairs

University of Exeter

Xiamen Vivohealths Technology Co., Ltd.

Boston University

University of Miami

Shanghai Jiao Tong University

Brandeis University

Anhui New Star Pharmaceutical Development Co., Ltd.

Xiaman University

Hongyun Biotech Co., Ltd.

The University of Pittsburg - of the Commonwealth of Higher Education

Xianming Deng

Nathanael Schiander Gray

Jianming Zhang

Nicholas Paul Kwiatkowski

Barun Okram

Ting Zhang

Jae Won Chang

Jinhua Wang

David Waller

Zhiyu Hu

Hwan Guen Choi

Wei Peng Huang

Hwan Geun Choi

Qingyan Xu

Zhou Deng

Xihuan Sun

Li Li

Amy Wojciechowski

Shuang Liu

Dandan Sun

Mohammad Iqbal Hossain Bhuiyan

Xiaoxing Huang

Zhixiang He

Bradley J Molyneaux

Yan Liu

Jinwei Zhang

Baoding Zhang

Xiaoyang Li

Shengcai Lin

Chensong Zhang

Chao Dong

Jingfang Zhang

Ping Liu

Wenjun Zhou

Izidore Lossos

Ruibao Ren

Yunzhan Li

Yue Lu

Dawang Zhou

Lanfen Chen

Fuqin Fan

Qiaofeng Kang

Xinrui Wu

Yanru Yang

Zhongji Zhuang

Zaiyou Yang

Bo Jiao

Jiaji Zhong

Rutao Cui

Chengqian Yin

Hongrui Wang

Wei Huang

Taoling Zeng

Yun Chen

Tingting Jiang

Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:

Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof

The present disclosure provides novel heteroaryl compounds of formula (VII). Such compounds are useful for the treatment of cancers.

Small molecule myristate inhibitors of Bcr-abl and methods of use

The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Type II raf kinase inhibitors

Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals: 

Provided herein are compositions and methods for the treatment and prevention of cancer, including melanoma.

STK19 inhibitors for treatment of cancer

The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

SPAK kinase inhibitors as neuroprotective agents

A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof

The present invention relates to a compound having the following formula, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, preparation method thereof, pharmaceutical composition comprising the same and use of the compound in the manufacture of a medicament for preventing or treating tumor, wherein the substituents are as defined in the specification. 

Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof

The invention relates to the field of medicinal chemistry, and to five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof. In particular, the invention relates to a type of compounds capable of specifically enhancing ubiquitination degradation of Ras proteins, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with Ras activity in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis. 

Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof

The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers. 

The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis. 

Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof

The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.

Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof

The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Pyrimido-diazepinone compounds and methods of treating disorders

The present invention provides novel heteroaryl compounds of formula (I) having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers. 

Small molecule myristate inhibitors of BCR-ABL and methods of use

Growing community of inventors

Fujian, China

Xianming Deng